Bifogade filer
PDF
Kurs
-3,90%
Likviditet
0,30 MSEK
Kalender
| Tid* | ||
| 2025-02-25 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-04 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-04-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-06 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-15 | - | Extra Bolagsstämma 2023 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2023-03-09 | - | Bokslutskommuniké 2022 |
| 2023-02-08 | - | Extra Bolagsstämma 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-16 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2022-06-15 | - | Årsstämma |
| 2022-04-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-18 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Extra Bolagsstämma 2021 |
| 2021-10-26 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-22 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-25 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2020-06-25 | - | Årsstämma |
| 2020-04-23 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-12 | - | Bokslutskommuniké 2019 |
| 2019-10-30 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Extra Bolagsstämma 2019 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-06 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2019-05-03 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-10-30 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-07 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-09 | - | X-dag ordinarie utdelning ACUVI 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-04-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-11-09 | - | Extra Bolagsstämma 2017 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-10 | - | Årsstämma |
| 2017-05-10 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-10-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Industri |
| Industri | Industriprodukter |
Acuvi AB today announces that its subsidiary Sensapex, part of the Acuvi Life Science Instrumentation business unit (LSI), has entered into strategic collaboration agreement with IVF2.0, a pioneering provider of AI software for assisted reproductive technology (ART). Purpose of the collaboration is to further bring AI assisted and enhanced intracytoplasmic sperm injection (ICSI) solutions to the human in vitro fertilization (IVF) market.
"We are looking forward to collaborating with the IVF2.0 team consisting of highly experienced and recognized IVF experts. IVF2.0 has developed the most advanced AI software for the assisted ICSI sperm selection, which we will integrate with the Sensapex cell manipulation and imaging platform. AI is a key ingredient towards complete ICSI automation, which is our long-term vision for the IVF market. Ultimately, the aim with automations is to improve consistency, precision and outcomes for IVF clinics and patients", said Dr Mikko Vähäsöyrinki, VP of LSI.
"Sensapex is a perfect match for us as we enhance our AI software offerings", said Dr Andrew Drakeley, CEO of IVF2.0. "Their unique and proprietary automated cell manipulation and imaging platform will provide the specialized instrumentation needed to implement our AI guidance smoothly and effectively in real-world IVF workflows".
The announced collaboration is part of the Sensapex go-to-market plan for the IVF market, which is one of the strategic growth initiatives for the LSI. Further information on the LSI strategy and IVF market entry will be provided at the upcoming Acuvi Capital Markets Day 12[th] of October 2023.
For more information, please contact:
Olof Stranding, CEO
ir@acuvi.com
Certified Adviser: Corpura Fondkommission AB
ca@corpura.se
+46 (0)72-252 34 51
About Acuvi
Acuvi is a group of companies that provides world-leading systems and technologies that enable higher precision and increased miniaturization. The customers can be found in, among other things, Life Science, the semiconductor industry and advanced optics. Acuvi's shares are traded on Nasdaq First North Growth Market.
www.acuvi.com
The information was submitted for publication by the above-mentioned contact person on 6 October 2023.